About

AmnioChor is a Biotech startup engaged in perinatal stem cell technologies, founded with a long term vision and operating on a near term mandate. The vision is the ability to satisfy the therapeutic needs of Mesenchymal and Epithelial stem cells as high volume commodities needed for new cures. The immediate mandate is to create the bank to serve that need through the cryopreservation of the living amniotic membrane of the placental sac. Regenerative Medicine with current and future Cellular Therapies will require a wealth of multipotent adult (non-embryonic) stem cells presented and retrieved from the placenta at birth, at their highest quality and preserved for future benefit.

The market to commercially harvest and freeze stem cells began in 1995 with the first umbilical cord blood bank, and has accelerated dramatically to approximately (2) million cord blood samples in private storage, and over 600,000 samples in public storage today.  The market through 2015 for cord blood therapeutics is estimated to exceed $13.5 billion and is expected to grow to reach $19.3 billion by 2020. However sadly, of the 4 million US births in 2014, less than 3% chose to bank their stem cells presented at this most opportune time.

AmnioChor has identified a source and method of acquiring and preserving the living amnion placental membrane, and the stem cells alive within. The amnion membrane is a fragile two cell layer structural tissue that possesses inherent therapeutic qualities, and also comprising a layer of Epithelial Stem Cells (EpSC), and a layer of what AmnioChor has termed, Amnion Derived Stem Cells (ADSC’s), which are Mesenchymal (MSC) in composition. AmnioChor’s Stem Cells differ significantly from cord blood stem cells (Hematopoietic Stem Cells, or HSC’s), and in augmenting HSC’s, will drive expansion of the private stem cell storage industry and autologous therapies to a completely new level. AmnioChor is creating a tissue bank called OmniBank, which is comprised of a personal bank for parents desiring to protect their child by autologous therapies, and a community bank for the donation of amnion tissue and the future of HLA matched allogeneic therapies. The Company has developed the best method of retrieving, preserving, isolating and manufacturing Mesenchymal Stem Cells by virtue of quality, and quantity. The Company’s model of creating a High Definition Human Leukocyte Antigen (HLA) tissue matching database, will enable the world to share the benefits of Amnion-Derived Stem Cells. AmnioChor’s breakthrough technologies will provide significant benefits to Regenerative Medicine and the burgeoning Cellular Therapy Industry, and will ultimately save patient’s lives.

AmnioChor is currently seeking Seed Round funding to complete tooling and initial AmnioCeptTM manufacturing for the Company’s Alpha commercialization validations. Next, Bridge Round funding will be sought to complete Beta clinical studies and regulatory compliance requirements. And finally, Round A funding will be secured for launch infrastructure and early operational sustenance. The Company envisions net profitability within the first (24) months of OmniBank operations, comprising fee-based private storage and a robust research market for HLA typed products derived from the community bank.

There are currently over 400 clinical trials in progress for new Regenerative Medicine and Cellular Therapies that utilize Mesenchymal Stem Cells. AmnioChor’s OmniBank will be a critical resource in the future and success of these therapies and industries. With a strong and growing US and foreign intellectual property portfolio, AmnioChor contemplates the OmniBank business model in a global context. The Company continues to develop the AmnioCeptTM product as universal to the world, and is actively seeking strategic collaborations and partnerships in Hong Kong, Singapore, India and the EU. With tandem activity in exploration of a second operational base in Hong Kong, AmnioChor is also focusing on the burgeoning markets of China, Singapore, Indonesia, Malaysia, and India. With over 40 million births in Asia in 2014, less than 1% chose to bank their cord blood stem cells. Therapies based on the tremendous values of the Amnion tissue, Mesenchymal and Epithelial stem cells represent a significant global void, and healthcare need and opportunity.

AmnioChor expanded its' executive offices early this year to become a founding member of the new MATTER Chicago healthcare incubator group, and continues to seek investors and strategic partners to fulfill the Company’s 2016 launch.